CHINA HUAJUN GP(00377): Arrange a plan to obtain the approval of the majority of the creditors required for the plan.
Chinese Hua Jun (00377) has announced that a meeting is planned to be held on February 25, 2025, aiming to consider and deliberate...
CHINA HUAJUN GP (00377) has issued an announcement stating that a meeting is planned to be held on February 25, 2025, with the aim of considering and approving (whether or not approved by the High Court and subject to modifications or conditions) the arrangements proposed between the company and the company's scheme creditors.
A total of 33 scheme creditors holding scheme claims totaling HK$739 million are set to vote at the scheme meeting (voting scheme claims), either in person or by electronic appointment of authorized representatives or agents.
23 scheme creditors (accounting for 69.70% of the total number of scheme creditors present at the scheme meeting and voting), holding a total of HK$714 million in voting scheme claims (accounting for 96.72% of the total value of the voting scheme claims), have voted in favor of the arrangement plan.
Therefore, the arrangement plan has obtained the necessary majority vote approval from the scheme creditors.
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025